Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: A multicenter dose-escalation study-Reference-Cited by-同舟云学术

Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: A multicenter dose-escalation study

Published:1999-05 Issue:5 Volume:10 Page:547-552
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Kouroussis C.,Xydakis E.,Potamianou A.,Giannakakis T.,Kakolyris S.,Agelaki S.,Sara E.,Malamos N.,Alexopoulos A.,Mavroudis D.,Samonis G.,Papadouris S.,Georgoulias V.,Panagos G.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/10/5/547/19477484/10-5-547.pdf

Reference21 articles.

1. Chemotherapy for metastatic disease;Henderson,1991

2. Systemic therapy of advanced breast cancer;Mouridsen;Drugs,1992

3. In vitro activity of Taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers;Zoli;Breast Cancer Res,1995

4. Treatment of patients with liver metastases;Fumoleau;Anticancer Drugs,1996

5. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide vs;fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: An Italian multicenter trial. J Clin Oncol,1988

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fever and breast cancer: A critical review of the literature and possible underlying mechanisms;Breast Disease;2021-07-15

2. Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patients;Breast Cancer Research and Treatment;2016-03-22

3. The effect of docetaxel on developing oedema in patients with breast cancer: a systematic review;European Journal of Cancer Care;2014-10-27

4. A multicenter phase I–II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer;The Breast;2013-12

5. BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers;Oncogene;2011-11-28